Hepatotoxicity
Hepatotoxicity is a phenotype of liver cell injury due to a multitude of causes including drugs, toxins, herbal and dietary supplements, and other agents. The goal of the AASLD Hepatotoxicity SIG is to promote and encourage research, education, and awareness regarding human hepatotoxicity. As such, individuals with any of the following interests and expertise are encouraged to partake in SIG activities.
- Drug hepatotoxicity
- Animal and cell culture models of hepatotoxicity
- Intrinsic and extrinsic mechanisms of hepatocyte death
- Pharmacogenomics
- Pharmacoepidemiology
- Herbal and dietary supplement induced liver injury
- Regulatory issues involving drugs and HDS products
- Acute Liver failure
- Liver transplantation
- Treatments for acute and chronic hepatotoxicity
- Liver histopathology
- Adverse drug events
- Drug pharmacokinetics and pharmacodynamics
- Nomenclature of hepatotoxicity
SIG Leadership
Chair
James Luyendyk, PhD
Vice Chair
Melissa Palmer, MD, FAASLD
Communication Lead
Max Garcia
Education Leads
Udayan Apte, PhD, DABT, FAASLD
Dina Halegoua-De Marzio, MD, FAASLD
Trainee Lead
Jacob Bogdanov, MD
At-Larges
Paul (Skip) Hayashi, MD, MPH, FAASLD
Jonny Sexton, PhD
Lauren Poole, PhD
Bharat Bhushan, PhD
Staff Liaisons
Akuender Dot, MPH
Julie Hoffman, MBA